Patients with peripheral arterial disease (PAD) and intermittent claudication often have coronary artery disease (CAD) and other comorbid medical problems. There is a paucity of information on the impact of coexistent medical conditions on exercise capacity and functional status in patients with PAD. This study examined the impact of CAD, diabetes, cigarette smoking, prior peripheral surgical revascularization and other medical conditions on claudication pain times and peak oxygen capacity (VO 2 ) during maximal effort treadmill testing in 119 male outpatient volunteers (ankle-brachial index (ABI) of 0.65 Ϯ 0.2, mean Ϯ SEM) with a history of Fontaine Stage II PAD. Smoking status was significantly related to ambulatory function. Current smokers had a lower peak VO 2 expressed in l/min than either former or never smokers (ANCOVA adjusted for age, p = 0.003). However, after adjustment for body weight, there was only a trend for a difference in peak VO 2 between current (13.2 Ϯ 0.5 ml/kg per min), former (14.2 Ϯ 0.4 ml/kg per min) and never (15.4 Ϯ 1.0 ml/kg per min) smokers (ANCOVA, p = 0.10). Current smokers had a shorter time to onset of claudication pain (p = 0.023) and shorter maximal claudication pain times (p = 0.029) than former or never smokers (p = 0.023). The ABI 1 min after cessation of exercise was also lower in smokers compared to former and never smokers (p = 0.018). There were no significant differences in functional performance measures or time to recovery from maximal claudication pain when patients were categorized on the presence or absence of CAD, diabetes, peripheral revascularization, arthritis, hypertension or dyslipidemia. Therefore, smoking adversely affected exercise capacity in these PAD patients, whereas the presence of CAD, diabetes and other medical problems had a relatively minor impact on exercise capacity. In conclusion, the relatively minor impact of comorbid medical conditions on walking ability in patients with PAD reflects the overwhelming limitation in ambulatory function due to the claudication pain.
Introduction
Peripheral arterial disease (PAD), a manifestation of atherosclerosis, is associated with moderate to severe impairment in walking ability. Major risk factors for PAD include cigarette smoking, hypertension, diabetes mellitus, elevated homocysteine levels, dyslipidemia, as well as advancing age. [1] [2] [3] [4] [5] A significant percentage of patients with PAD also have concomitant coronary artery disease (CAD) and cerebral vascular disease. 1, 6 Cigarette smoking, CAD, diabetes mellitus, and other concurrent medical conditions may contribute to the impaired ambulatory function in patients with PAD. In previous studies from our laboratory, cigarette smoking worsens claudication distances 7 and lowers daily physical activity 8 in patients with PAD and intermittent claudication. However, it is less clear whether other risk factors and comorbid medical conditions reduce ambulatory function in this disabled population. [9] [10] [11] The purpose of this study was to examine the effect of CAD, diabetes, cigarette smoking, prior peripheral surgical revascularization and other medical conditions on functional performance during treadmill testing in PAD patients with intermittent claudication. We hypothesized that cigarette smoking, CAD, diabetes and other CAD risk factors and medical conditions would be associated with impaired ambulatory function.
Methods

Subjects
This study was approved by the institutional review board of the University of Maryland and all patients signed informed consent prior to their participation.
Outpatient volunteers with a history of PAD and intermittent claudication (Fontaine Stage II) were recruited from the vascular surgery clinics at the University of Maryland Hospital and the Baltimore VA Medical Center, as well as from healthcare providers in the Baltimore metropolitan area, and via media advertisements targeting patients with PAD for participation in a 6-month hospital-based exercise training study. 12 Patients were briefly interviewed over the phone. The London School of Hygiene Cardiovascular (Rose) Questionnaire 13 was used to select patients suffering from intermittent claudication. Patients whose responses suggested that they suffered claudication had their anklebrachial index (ABI) measured in our laboratory.
A total of 225 patients with symptomatic intermittent claudication and an ABI Ͻ 0.97 received a comprehensive medical evaluation including history and physical examination, blood chemistries, electrocardiogram, and screening exercise treadmill test. As described in a previous report from our laboratory, 14 79 patients were medically ineligible: 22 due to cardiac disease, i.e. unstable angina or severe silent ischemia during the screening treadmill testing, 15 12 with severe PAD (Fontaine Stages III and IV), eight with poorly controlled hypertension (resting BP Ͼ 180/95 or severe exercise-induced hypertension with a systolic BP Ն240 mmHg or diastolic Ն120 mmHg, even after medication adjustment), five with poorly controlled diabetes (fasting blood sugar Ն200 mg/dl after referral to their physicians for medication readjustment), and the rest due to a variety of other medical problems. Five patients refused further testing. On a subsequent visit, 141 patients (119 men, 22 women) were brought back for maximal effort treadmill testing with measurement of peak aerobic capacity (VO 2 ). In the initial analyses it became apparent that there was inadequate power to compare functional parameters in the 22 women categorized by the presence or absence of the comorbid medical conditions. Therefore, in this study, we report data only on the 119 men (age 68 Ϯ 1 years, mean Ϯ SEM). In all, 54% of the study population was African American.
Measurement of ABI
Following 10 min of supine rest, the blood pressure was measured in the brachial artery of both arms, and in the posterior tibial and dorsalis pedis arteries of the symptomatic leg(s) by Doppler ultrasound techniques. 16 The artery yielding the higher pressure in the more severely diseased leg and the brachial artery yielding the higher systolic pressure were used to calculate the ABI.
Treadmill testing
Screening exercise treadmill test
The patients performed a constant speed (2 miles/h, 3.2 km/h), progressive graded treadmill test to maximal claudication pain to screen for cardiovascular disease. 16 This screening test also served as a familiarization treadmill test. The test was started with the treadmill at 2 miles/h (3.2 km/h), and 0% grade, and the grade was then increased 2% every 2 min. Patients indicated the onset of claudication pain and when maximal claudication pain occurred using a four-point pain scale. Test termination criteria included maximal claudication pain, exercise-induced systolic BP Ն240 mmHg or diastolic Ն120 mmHg, exercise-induced angina, marked asymptomatic exercise-induced ST segment depression on the electrocardiogram (Ն2 mm), a 20-mmHg drop in systolic BP during exercise, and complex arrhythmias.
Maximal effort exercise treadmill test with measurement of peak VO 2 On a subsequent visit, a maximal effort exercise treadmill test with measurement of peak VO 2 was performed. 12 The progressive exercise protocol was identical to that used in the screening test except that ventilation was collected for measurement of CO 2 production and O 2 consumption (SensorMedics 2900 Metabolic Cart, Yorba Linda, CA, Vascular Medicine 2001; 6: 157-162 USA). The final two 20-s values of oxygen consumption were averaged for the determination of the peak O 2 consumption. The ABI was measured at 1 min following the treadmill tests and patients indicated when their claudication pain had disappeared (claudication recovery time).
Measurement of cardiac risk factors
After a 12-14-h overnight fast, blood samples were drawn into tubes containing chilled EDTA (1 mg/dl of blood) for measurement of plasma glucose and lipoprotein lipid levels. Plasma lipoprotein lipid concentrations were measured enzymatically. 17, 18 The fasting glucose concentrations were measured as part of the automated chemistry battery. Blood pressures were measured in both arms in the supine position after a 10-min rest period using a Dinamap, as previously described. 8 All reported blood pressure, lipoprotein and glucose values were obtained while patients were taking their regular medications.
Disease criteria
The presence or absence of the medical comorbidities was ascertained on the basis of history and physical examination, blood chemistry tests, exercise treadmill tests, and a review of hospital and healthcare provider medical records. To decrease misclassification, the patient self-report of comorbid disease required confirmation with either medical record review or direct measured evidence of the disease. The patients were classified into three smoking categorizes: current smoker, former smoker (no cigarette smoking for Ͼ 1 year) and never smokers. The number of pack years smoked was calculated from self-reported data. CAD was defined as a history of myocardial infarction, angioplasty, coronary artery bypass graft (CABG) surgery or use of antianginal medications. Diabetes was defined as a fasting blood glucose Ն7.00 mmol/l (126 mg/dl) on two or more occasions, or use of oral hypoglycemic agents, or insulin. Hypertension was defined as a systolic BP Ն140 mmHg, or diastolic Ն90 mmHg on two or more occasions, or use of anti-hypertensive medications. Dyslipidemia was defined as a low density lipoprotein cholesterol concentration (LDL-C) Ն4.14 mmol/l (100 mg/dl), or triglyceride (TG) concentration Ն4.52 mmol/l (400 mg/dl), or high density lipoprotein cholesterol concentration (HDL-C) Յ0.91 mmol/l (35 mg/dl), or use of lipid-lowering medications. 19 Arthritis was defined as the patient self-report of arthritis confirmed by medical record review.
Statistics
Data were analyzed using PC-SAS version 6.12 (SAS Institute, Cary, NC, USA). Due to the difference in age among the three smoking groups (current smokers, former and never smokers), analyses were performed using analysis of covariance (ANCOVA), adjusting for age (SAS PROC GLM; SAS Institute, Inc., Cary, NC, USA) to compare functional parameters in the presence or absence of the comorbid medical conditions. For comparisons involving smoking status (never, former, current smokers), Scheffe's post-hoc tests were used to perform pairwise comparisons of the age-adjusted mean responses between levels of smoking. Data are means Ϯ standard error of the mean (SEM).
Results
The prevalence of selected comorbid medical conditions in the 119 male patients with PAD is summarized in Table 1 . A total of 90% of the patients were either current (40%) or former (50%) smokers. The number of pack years smoked was similar in the current and former smokers (46 Ϯ 5 versus 53 Ϯ 4 pack years, p = 0.63). In the total population, the mean ABI was 0.65 Ϯ 0.2, the mean time to onset of claudication pain occurred at 192 Ϯ 17 seconds, and maximal pain at 422 Ϯ 23 seconds. On average, patients took 451 Ϯ 23 seconds for the claudication pain to subside after maximal exercise. The mean peak VO 2 for the population was 1.14 Ϯ 0.03 l/min (13.9 Ϯ 0.3 ml/mg per min).
Physical characteristics and the supine rest ABI measures for the patients categorized by their smoking status and medical comorbidities are summarized in Table 2 . Current smokers were younger (63.9 ± 1.0 years) than the former (69.6 Ϯ 0.9 years) and never (70.1 Ϯ 1.9 year, p Ͻ 0.0001) smokers, and had a lower weight and body mass index (BMI) than the non-smokers (p = 0.001). Current smokers also had a lower ABI than non-smokers (p = 0.0012) and a lower systolic BP than former and never smokers (p = 0.027). The patients with hyperlipidemia were more obese than those without hyperlipidemia (p = 0.001). Otherwise, there were no significant differences in physical characteristics or resting supine ABI when patients were categorized on the basis of medical comorbidities.
Physical performance measures during a maximal effort exercise treadmill test with the patients categorized by their smoking status and medical comorbidities are summarized in Table 3 . Smoking status was significantly related to ambulatory function. Current smokers had a lower peak VO 2 expressed in l/min than either former or never smokers (ANCOVA adjusted for age, p = 0.003). However, after adjustment for body weight, there was only a trend for a difference in VO 2 ml/mg per min between current (13.2 Ϯ 0.5 ml/kg per min), former (14.2 Ϯ 0.4 ml/kg per min) and never (15.4 Ϯ 1.0 ml/kg per min) smokers (ANCOVA, p = 0.10). Current smokers had a shorter time to onset of claudication pain than former or never smokers (ANCOVA p = 0.023) and shorter maximal claudication pain times than the former and never smokers (ANCOVA, p = 0.029). The ABI 1 min after cessation of exercise was also lower in current smokers compared to former and never smokers (ANCOVA, p = 0.018). There were no significant differ- Data are mean ± SEM adjusted for age; statistical comparisons performed using ANCOVA (adjusted for age). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ABI, ankle/brachial index. BMI in kg/m 2 ; blood pressure in mmHg.
Significance: a , current smokers different from non-smokers (former and never smokers), p = 0.001; b , current smokers different from non-smokers (former and never smokers), p = 0.027; c , current smokers different from non-smokers (former and never smokers), p = 0.0012; d , hypertensives significantly different from non-hypertensives, p = 0.0001; e , hypertensives significantly different from non-hypertensives, p = 0.001; f , hyperlipidemics significantly different from nonhyperlipidemics, p = 0.0010. ences in mean time to recovery from claudication pain in the three groups. Contrary to our hypothesis, there were no significant differences in these functional performance measures when patients were categorized on the basis of the presence or absence of CAD. Furthermore, in a subgroup analysis, functional performance was similar in the 20 PAD patients with concomitant CAD who had undergone CABG surgery and the 30 patients with PAD and CAD who were treated with medical therapy (Table 4) . Similarly, there were no significant differences in functional performance when patients were categorized on the presence or absence of peripheral revascularization, diabetes mellitus, hypertension, hyperlipidemia, and arthritis.
Discussion
Our hypothesis that cigarette smoking impairs functional performance in PAD patients with intermittent claudication was supported, confirming prior investigations. 7 However, our a priori hypothesis that other risk factors and comorbid Data are mean ± SEM adjusted for age; statistical comparisons performed using ANCOVA (adjusted for age). Claudication times in seconds.
Significance: a , current smokers different from former and never smokers, p = 0.003; b , never smokers different from former and current smokers, p = 0.023; c , never smokers different from former and current smokers, p = 0.029; d , current smokers different from former and never smokers, p = 0.018. conditions would adversely impact on ambulatory function was not supported. These results highlight the adverse effects of cigarette smoking on function in PAD patients with claudication. The current smokers had a lower resting ABI, shorter time to onset of claudication pain, lower time to maximal claudication pain, and lower ABI 1 min after maximal exercise than the former and never smokers. In prior studies performed in our laboratory on a separate population of Vascular Medicine 2001; 6: 157-162 patients with PAD, the difference in functional and hemodynamic parameters was even more striking between smokers and former smokers than those observed in the current study. 7 In that study, smokers and former smokers differed in resting ABI, time to onset of claudication pain, time to maximal claudication pain, peak VO 2 (ml/kg per min) and time to recovery from claudication pain. Other studies in our laboratory demonstrated that free living daily physical activity was 35% lower in cigarette smokers with PAD than non-smoking PAD patients. 8 These cross-sectional studies of the adverse effects of smoking on exercise capacity in smoking claudicants are supported by intervention studies that demonstrate that smoking cessation enhances walking ability in claudicants, 20 decreases progression of atherosclerotic disease, and increases survival. 21 Potential mechanisms underlying the adverse effects of chronic cigarette smoking on exercise function include abnormal central (cardiac) and pulmonary function, accelerated peripheral atherosclerosis, vasoconstriction, impaired O 2 delivery to the exercising leg musculature, abnormalities in muscle chemistry or function, or a combination of these factors. In any event, regardless of the mechanism(s), chronic cigarette smoking adversely affects the exercise capacity of patients with PAD who are already limited by intermittent claudication.
Several studies have examined the impact of diabetes and other comorbid medical conditions on walking ability in patients with intermittent claudication. Carter et al compared the time to onset of claudication pain and maximal walking distance on the treadmill in 56 PAD patients categorized by the presence of unilateral versus bilateral disease, proximal versus distal arterial obstruction, presence of ischemic heart disease, presence of diabetics and smoking status. 9 They found no significant differences in walking ability between patients characterized by the presence or absence of these conditions. They did report negative correlations between age and pain-free walking distance and negative correlations between percentage body fat and treadmill distance. In an exercise training study of patients with PAD, Ekroth et al reported that the increase in walking ability with training was independent of the location of the atherosclerotic lesion or the presence of diabetes mellitus. 10 Rosfors et al reported negative relationships between blood glucose and cortisol levels with walking distance. 11 Collectively, these studies suggest that smoking adversely affects exercise capacity in patients with PAD, whereas diabetes and other medical problems have a relatively minor impact on functional performance in patients with PAD. We speculate that the relatively minor impact of comorbid medical conditions on walking ability in rigorously screened patients with PAD reflects the overwhelming limitation in ambulatory function due to the claudication pain.
The peak VO 2 of 14 ml/kg per min for the population of PAD patients we studied is similar to that reported by other investigations of patients with PAD. 22, 23 The peak VO 2 in PAD patients is substantially lower than the mean peak VO 2 of 23 ml/kg per min seen for healthy sedentary men aged 70 years old tested in our laboratory. 24 Indeed, the severe limitation in exercise capacity in PAD patients becomes more apparent when one realizes that the peak VO 2 values in PAD patients are similar to values of patients with congestive heart failure referred for heart transplantation. 25 As a result of the poor exercise capacity, patients with intermittent claudication have functional impairments that interfere with their ability to perform household chores and other activities. Three population-based studies have examined functional disability in older individuals with evidence of PAD. In data pooled from the three sites in the Established Populations for Epidemiologic Studies of the Elderly (EPESE), the prevalence of moderate disability based on the Rosow-Breslau functional health scale 26 was higher in claudicants than in those without claudication. 27 In the Multicenter Study of Osteoporotic Fractures, a higher percentage of elderly women with an ABI Ͻ0.90 reported difficulty in performing heavy housework and in walking two to three blocks on level ground than women with an ABI Ͼ0.90. 28 Similarly in the Women's Health and Aging Study, older women with asymptomatic PAD (ABI Ͻ0.90) had impaired lower extremity functioning, including slower walking velocity, poorer standing balance, slower chairstand times and fewer blocks walked per week, even after adjustment for medical comorbidities. 29 Interestingly, the majority of the older women with low ABI values in the Multicenter Study of Osteoporotic Fractures and in the Women's Health and Aging Study did not report symptoms of claudication, thereby demonstrating that even mild, subclinical PAD results in decreased mobility and functional status.
There are a number of study limitations that must be considered. First, this was not a randomly selected population of patients with Fontaine Stage II PAD, and the results obtained in our population may not be applicable to other populations. Secondly, in order to obtain maximal effort measures of peak VO 2 and claudication, some patients with severe comorbid medical conditions, such as those with severe symptomatic CAD, poorly controlled hypertension and active cancer, were excluded from the study. 15 Inclusion of these patients might have altered the results. Thirdly, our former smokers had comparable pack years of smoking as the current smokers, and there were few never smokers in our population. This may have resulted in an underestimate of the adverse effects of cigarette smoking on functional performance. Fourthly, the diagnostics criteria and definition of comorbid illness may affect the statistical analyses. For example, increasing the LDL-C concentration criteria for hyperlipidemia from 100 mg/dl (the treatment goal for patients with known coronary disease) to 160 mg/dl, would decrease the number of patients with hyperlipidemia from 108 to 79. The overall results of the analyses were the same, however, with either definition of hyperlipidemia (data not shown). Misclassification of the presence or absence of a given comorbid disease also affects the analyses. For example, knee X-rays were not obtained as part of the research protocol and clinical X-ray reports were not reviewed, thereby resulting in a potential misclassification of lower extremity arthritis in some of the patients. Another study limitation is that we did not apply the Bonferroni method to adjust for the number of statistical analyses performed. Finally, our analyses could only be performed in the male patients with PAD, and studies in older women with PAD may yield different results.
In summary, the primary findings of this investigations were that: (1) current cigarette smokers had shorter claudication pain times, and a lower ABI at rest and 1 min after exercise than former and current smokers; and (2) there were no significant differences in peak VO 2 or claudication times when patients were categorized on the basis of presence or absence of CAD, diabetes mellitus, or peripheral revascularization. The relatively minor impact of comorbid medical conditions on ambulatory performance in PAD patients may reflect the overwhelming limitation in ambulatory function due to the claudication pain.
